Foundayo Introduces Full Color Coding for All 6 Doses – Are Pharmacists Noticing Confusion Yet?
Drug companies know that using different colors helps stop mistakes at the pharmacy. Color coding acts as a vital…
-
-
FDA Approves Foundayo as Eli Lilly Expands Oral Weight Loss Portfolio
The Federal Food and Drug Administration approved Foundayo for chronic weight management on April 1, 2026. This oral medication…
-
Semaglutide Market Size, Growth, and Forecast 2026–2027
Semaglutide is currently changing how doctors treat heart and metabolic health. This drug started as a simple treatment for…
-
Eli Lilly’s Foundayo Joins TrumpRx Platform Following Expedited FDA Approval
The Food and Drug Administration approved Eli Lilly’s once daily weight loss pill, Foundayo, on April 1, 2026. This…
-
Foundayo (Orforglipron): FDA Approves First Once-Daily GLP-1 Pill for Weight Loss
The FDA’s recent approval of Foundayo (orforglipron) is a genuine turning point for anyone who has struggled with weight…
-
GLP-1 Receptor Agonists Show Broad Promise for People Living with HIV, but Access Remains a Critical Barrier
New medical data shows that GLP-1 drugs help people living with HIV in many ways. These medications improve liver…
-
GLP-1 Medications Show Promise for Opioid Use Disorder, but Evidence Remains Limited
Doctors now look at popular weight loss drugs to help treat opioid addiction. These medications, known as GLP-1 agonists,…
-
13 Science-Backed Ways GLP-1 Medications May Benefit the Body
Doctors now use GLP-1 drugs to change how they treat the human body. These medicines first helped people manage…
-
Genetic and Ancestral Differences in GLP-1 Drug Response Identified in Large Biobank Study
A major new study shows that a person’s background can change how they react to popular weight-loss drugs. Researchers…
-
Hims & Hers Partners with Novo Nordisk to Expand Access to FDA-Approved GLP-1 Medications
Hims and Hers Health recently launched a massive expansion of its telehealth services. The platform now offers a wide…
